Welcome to the e-CCO Library Archive!

Filter:
OP007.

Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn's disease patients who are anti-TNF inadequate responders: Results from the TOSCA study

Authors:

G. D'Haens1, S. Vermeire2, F. Cataldi3, H. Vogelsang4, M. Allez5, P. Desreumaux6, A. Van Gossum7, D. Baumgart8, W.J. Sandborn9, K.J. Gorelick3, R. Ransohoff10, O. Stuve11, J. Cheng3, S. Rivers3, G.M. Comer3, B. Jin3, B. Jin3, V. Pradhan3, M. Hassan-Zahraee3, A. Kaminski3, W. Reinisch4, 1University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands, 2University Hospital Leuven, Gastroenterology, Leuven, Belgium, 3Pfizer Inc., Gastroenterology, Cambridge, United States, 4Medical University of Vienna, Internal Medicine/Gastroenterology, Vienna, Austria, 5Hopital Saint-Louis – APHP, Gastroenterologie, Paris, France, 6CHU de Lille, Gastroenterologie, Lille, France, 7Erasme Hospital, Free University of Brussels, Gastroenterology, Brussels, Belgium, 8Humboldt-University of Berlin, Charite Medical School, Berlin, Germany, 9University of California San Diego, Division of Gastroenterolgy, San Diego, United States, 10Cleveland Clinic, Neurology, Cleveland, OH, United States, 11University of Texas, Neurology, Dallas, TX, United States

OP007

Deep remission in Crohn´s disease does not prevent disease relapse after withdrawal of anti-TNFa therapy

Authors:

M. Bortlik*1, D. Duricová1, N. Machkova1, V. Hruba1, M. Lukas1, K. Mitrova1, I. Romanko1, V. Bina2, M. Lukas1

1ISCARE and Charles University, IBD Clinical and Research Centre, Prague, Czech Republic, 2Faculty of Management in Jindrichuv Hradec, University of Economics in Prague, Department of Exact Methods, Jindrichuv Hradec, Czech Republic

OP008.

The cost of investigations and medical treatment including biological therapy in a European inception cohort from the biological era – An ECCO-EpiCom study

Authors:

J. Burisch1, I. Kaimakliotis2, D. Duricova3, N. Thorsgaard4, V. Andersen5,6,7, K.R. Nielsen8, E.V. Tsianos9, K. Ladefoged10, Y. Bailey11, R. D'Incà12,13, L. Kupcinskas14, S. Turcan15, F. Magro16,17,18, A. Goldis19, E. Belousova20, V. Hernandez21, S. Almer22,23, J. Halfvarson24,25, S. Sebastian26, E. Langholz27, S. Odes28, P. Munkholm1, 1Herlev University Hospital, Department of Gastroenterology, Herlev, Denmark, 2Nicosia private practice, Private practice, Nicosia, Cyprus, 3Charles University, IBD Center ISCARE, Prague, Czech Republic, 4Herning Central Hospital, Department of medicine, Herning, Denmark, 5Viborg Regional Hospital, Medical Department, Viborg, Denmark, 6University of Southern Denmark, Institute of Regional Health Research, Odense, Denmark, 7Hospital of Southern Jutland, Medical Department, Aabenraa, Denmark, 8The National Hospital of the Faroe Islands, Medical Department, Thorshavn, Faroe Islands, 9University Hospital, Ioannina, 1st Division of Internal Medicine and Hepato-Gastroenterology Unit, Ioannina, Greece, 10Dronning Ingrids Hospital, Medical Department, Nuuk, Greenland, 11Adelaide and Meath Hospital, TCD, Department of Gastroenterology, Dublin, Ireland, 12Azienda Ospedaliera, Università di Padova, UO Gastroenterologia, Padova, Italy, 13On behalf of the EpiCom Northern Italy centre based in Crema & Cremona, Firenze, Forlì, Padova and Reggio Emilia, Northern Italy, Italy, 14Lithuanian University of Health Sciences, Institute for Digestive Research, Kaunas, Lithuania, 15State University of Medicine and Pharmacy of the Republic of Moldova, Department of Gastroenterology, Chisinau, Moldova, Republic of, 16Oporto Medical School, Institute of Pharmacology and Therapeutics, Porto, Portugal, 17Hospital de São João, Department of Gastroenterology, Porto, Portugal, 18University of Porto, Institute for molecular and cell biology, Porto, Portugal, 19University of Medicine ‘Victor Babes’, Clinic of Gastroenterology, Timisoara, Romania, 20Moscow Regional Research Clinical Institute, Department of Gastroenterology, Moscow, Russian Federation, 21Complejo Hospitalario Universitario de Vigo, Gastroenterology, Vigo, Spain, 22County council of Östergötland, Department of Gastroenterology/UHL, Linköping, Sweden, 23Karolinska Institutet, Division of Gastroenterology and Hepatology, Stockholm, Sweden, 24Örebro University, School of Health and Medical Sciences, Örebro, Sweden, 25Örebro University Hospital, 24. Department of Medicine, Division of Gastroenterology, Örebro, Sweden, M, 26Hull Royal Infirmary, Hull and East Yorkshire NHS Trust & Hull and York Medical School, Hull, United Kingdom, 27Gentofte Hospital, Department of Medical Gastroenterology, Copenhagen, Denmark, 28Soroka Medical Center and Ben Gurion University of the Negev, Department of Gastroenterology and Hepatology, Beer Sheva, Israel

OP008

The first prospective Australian population-based study of newly diagnosed IBD identifies frequent use of immunomodulators, low surgery rates and high cost from medications and investigations.

Authors:

O. Niewiadomski*1, C. Studd1, C. Hair2, J. Wilson1, J. Ding1, N. Heerasing2, A. Ting2, K. Ross2, J. Santamaria3, E. Prewett2, P. Dabkowski2, S. Alexander2, D. Dowling2, B. Allen2, B. Popp4, G. Alex5, T. Catto-Smith5, J. McNeill6, W. Connell1, P. Desmond1, S. Bell1

1St Vincent's Hospital, Gastroenterology, Fitzroy, Australia, 2Barwon Health, Gastroenterology, Geelong, Australia, 3St Vincent's Hospital, Intensive Care Unit, Fitzroy, Australia, 4St John of God Pathology, Pathology, Geelong, Australia, 5Royal Children's Hospital, Gastroenterology, Parkville, Australia, 6Monash University, Preventative Medicine and Public Health, Melbourne, Australia

OP009.

Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extension

Authors:

W. Reinisch1,2, P. Gibson3, W.J. Sandborn4, B.G. Feagan5, C. Marano6, R. Strauss6, J. Johanns6, H. Zhang6, L. Padgett6, J.-F. Colombel7, J. Collins8, P. Rutgeerts9, 1Universitäts­klinik für Innere Medizin III, Vienna, Austria, 2McMaster University, Hamilton, ON, Canada, 3Alfred Hospital, Melbourne, VIC, Australia, 4University of California San Diego, La Jolla, CA, United States, 5Robarts Research Institute, University of Western Ontario, London, ON, Canada, 6Janssen Research & Development, LLC, Spring House, PA, United States, 7Hôpital Claude Huriez, Lille Cedex, France, 8Oregon Health Sciences University, Portland, OR, United States, 9University Hospital, Gasthuisberg, Leuven, Belgium

OP009

Unchanged surgery and hospitalization rates in an East-West European inception cohort despite differences in use of biologicals - 3-year follow-up of the ECCO-EpiCom cohort

Authors:

J. Burisch*1, I. Kaimakliotis2, D. Duricova3, L. Kievit4, J.F. Dahlerup5, R. Salupere6, K.R. Nielsen7, P. Manninen8, E.V. Tsianos9, Z. Vegh10, S. Odes11, R. D'Inca12, L. Kupcinskas13, S. Turcan14, F. Magro15, 16, 17, A. Goldis18, V. Hernandez19, J. Halfvarson20, N. Arebi21, E. Langholz22, P.L. Lakatos10, P. Munkholm23

1Hvidovre University Hospital, Gastrounit, Medical section, Hvidovre, Denmark, 2Nicosia Private practice, Nicosia Private practice, Nicosia, Cyprus, 3Charles University, IBD Center ISCARE, Prague, Czech Republic, 4Herning Central Hospital, Department of medicine, Herning, Denmark, 5Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark, 6Tartu University Hospital, Division of Endocrinology and Gastroenterology, Tartu, Estonia, 7The National Hospital of the Faroe Islands, Medical Department, Thorshavn, Faroe Islands, 8Tampere University Hospital, Department of Gastroenterology and Alimentary Tract Surgery, Tampere, Finland, 9University Hospital, Ioannina, 1st Division of Internal Medicine and Hepato-Gastroenterology Unit, Ioannina, Greece, 10Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 11Soroka Medical Center and Ben Gurion University of the Negev, Department of Gastroenterology and Hepatology, Beer Sheva, Israel, 12On behalf of the EpiCom Northern Italy, Florence, Forlì, and Padova, Northern Italy, Italy, 13Lithuanian University of Health Sciences, Institute for Digestive Research, Kaunas, Lithuania, 14State University of Medicine and Pharmacy of the Republic of Moldova, Department of Gastroenterology, Chisinau, Moldova, Republic of, 15University of Porto, Institute for molecular and cell biology, Porto, Portugal, 16Hospital de São João, Department of Gastroenterology, Porto, Portugal, 17Oporto Medical School, Institute of Pharmacology and Therapeutics, Porto, Portugal, 18University of Medicine ←Victor Babes→, Clinic of Gastroenterology, Timisoara, Romania, 19Complexo Hospitalario Universitario de Vigo, Gastroenterology Department, Vigo, Spain, 20Faculty of Medicine and Health, Örebro University, Department of Gastronterology, Örebro, Sweden, 21St Mark's Hospital, Gastroenterology, London, United Kingdom, 22Gentofte Hospital, Department of Medical Gastroenterology, Copenhagen, Denmark, 23Herlev University Hospital, Department of gastroenterology, Herlev, Denmark

OP01. Card9 is a crucial adapter protein for gastro-intestinal immune response
OP010.

AlphaE integrin expression as a predictive biomarker for induction of clinical remission by etrolizumab: Analysis of a phase II trial in moderate-to-severely active ulcerative colitis

Authors:

M. Keir1, G.W. Tew1, D. Luca1, J. Eastham-Anderson1, L. Diehl1, J.G. Egen1, S. Vermeire2, J.C. Mansfield3, C.A. Lamb3, J. Panes4, D.C. Baumgart5, S. Schreiber6, I. Dotan7, W.J. Sandborn8, G. De Hertogh2, J.A. Kirby3, G. Van Assche2, P. Rutgeerts2, S. O'Byrne1, 1Genentech, Research and Early Development, South San Francisco, United States, 2KU Leuven, Division of Gastroenterology, Leuven, Belgium, 3Royal Victoria Infirmary, Gastroenterology, Newcastle upon Tyne, United Kingdom, 4Hospital Clínic Barcelona, Gastroenterology, Barcelona, Spain, 5Humboldt-University of Berlin, Charite Medical School, Berlin, Germany, 6Christian Albrechts University, Institute of Clinical Molecular Biology, Kiel, Germany, 7Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel, 8University of California, San Diego, Gastroenterology, San Diego, United States

OP010

Medication-induced microscopic colitis: do recency and duration of use matter?

Authors:

B.P.M. Verhaegh*1, 2, F. de Vries3, 4, A.A. Masclee1, 2, A. Keshavarzian3, A. de Boer3, P. Souverein3, D.M. Jonkers1, 2, M.J. Pierik1

1Maastricht University Medical Center+, Internal Medicine - Division of Gastroenterology-Hepatology, Maastricht, Netherlands, 2Maastricht University Medical Center+, NUTRIM, School for Nutrition, Toxicology and Metabolism, Maastricht, Netherlands, 3Utrecht Institute of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht, Netherlands, 4Maastricht University Medical Center+, Clinical Pharmacology & Toxicology, Maastricht, Netherlands

OP011.

Tralokinumab (CAT-354), an interleukin 13 antibody, in moderate to severe ulcerative colitis: A phase 2 randomized placebo-controlled study

Authors:

S. Danese1, J. Rudzinski2, W. Brandt3, J.L. Dupas4, L. Peyrin-Biroulet5, Y. Bouhnik6, D. Kleczkowski7, P. Uebel8, M. Lukas9, M. Knutsson10, F. Erlandsson10, M. Berner Hansen10, S. Keshav11, 1Istituto Clinico Humanitas, IBD Center, Milan, Italy, 210 Wojskowy Szpital Kliniczny z Poliklinik?, Kliniczny Oddzia? Gastroenterologii, Warsaw, Poland, 3Facharzt für Innere Medizin, Internal Medicine, Potsdam, Germany, 4CHU d'Amiens Hôpital Nord, Hepato-Gastroenterology, Amiens, France, 5CHU Nancy Brabois, Gastrology, Vandoeuvre les Nancy, France, 6Hopital Beaujon – APHP, Gastroenterologie, Clichy, France, 7Endoskopia Sp.z o.o., Gastroenterology, Sopot, Poland, 8Haus der Gesundheit, Internal Medicine, Ludwigshafen, Germany, 9Iscare, Gastroenterology, Prague, Czech Republic, 10AstraZeneca, Innovative Medicines, Mölndal, Sweden, 11John Radcliffe Hospital, Translational Gastroenterology Unit, Oxford, United Kingdom

OP011

Budesonide MMX® 9 mg for Inducing Remission in Patients with Mild-to-Moderate Ulcerative Colitis Not Adequately Controlled with Oral 5-ASAs

Authors:

D.T. Rubin*1, R.D. Cohen1, W.J. Sandborn2, G.R. Lichtenstein3, J. Axler4, R. Riddell5, C. Zhu6, A.C. Barrett6, E. Bortey6, W.P. Forbes7

1The University of Chicago, Medicine, Chicago, United States, 2University of California San Diego, UC San Diego Health System, San Diego, United States, 3University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States, 4Toronto Digestive Disease Associates Inc., Toronto, Canada, 5Mt. Sinai Hospital, Pathology and Molecular Medicine, Toronto, Canada, 6Salix Pharmaceuticals, Inc., Raleigh, United States, 7Salix Pharmaceuticals Inc., Raleigh, United States

OP012.

Epigenetic control of colonic inflammation via the methyl-binding protein Mbd2

Authors:

G.-R. Jones1, P. Cook2, A. MacDonald2, 1University of Edinburgh, Institute of Immunology and infection research, Edinburgh, United Kingdom, 2Manchester Collaborative Centre for Inflammation Research, Faculty Life Sciences, Manchester, United Kingdom

OP012

Information needs and concerns of patients with Inflammatory Bowel Disease: What can we learn from participants of a national clinical cohort?

Authors:

V. Pittet*1, C. Vaucher1, M.H. Maillard2, M. Girardin3, P. de Saussure3, G. Rogler4, P. Michetti5

1Institute of Social and Preventive Medicine, Healthcare Evaluation Unit, Lausanne, Switzerland, 2Lausanne University Hospital, Department of Gastroenterology & Hepatology, Lausanne, Switzerland, 3Geneva University Hospital, Division of Gastroenterology & Hepatology, Geneva, Switzerland, 4University of Zurich, Gastroenterology and Hepatology, Zurich, Switzerland, 5Clinique La Source-Beaulieu, Crohn and Colitis Center, Lausanne, Switzerland

OP013.

Status of ER stress and autophagy in Crohn's disease: From genetics to functional read-outs

Authors:

K. Nys1, W. Vanhove1, I. Cleynen1, M. Ferrante1, G. Van Assche1, P. Rutgeerts1, P. Agostinis2, S. Vermeire1, 1Department of Clinical and Experimental Medicine, KU Leuven, Translational Research in GastroIntestinal Disorders, Leuven, Belgium, 2KU Leuven, Cellular & Molecular Medicine, Leuven, Belgium

OP013

Patient-relevant Endpoints in Inflammatory Bowel Diseases - Have Changes Occurred in Germany over the Past Twelve Years?

Authors:

A. Stallmach*1, U. Dennler2, U. Marschall3, C. Schmidt4

1University Hospital Jena, Clinic for Internal Medicine IV, Jena, Germany, 2Friedrich Schiller University Jena, Geschäftsbereich Medizincontrolling, Jena, Germany, 3BARMER GEK Hauptverwaltung 1100, Kompetenzzentrum Medizin und Versorgungsforschung, Berlin, Germany, 4Clinic for Internal Medicine IV, Jena University Hospital, Jena, Germany

OP014.

Early endoscopic, laboratory and clinical predictors of poor disease course in pediatric ulcerative colitis (UC)

Authors:

D. Turner1, C. Griffiths2, J.C. Gana3, R. Shaoul4, R. Shamir5, E. Shteyer6, T. Bdolah-Abram6, A. Schechter1, 1Shaare Zedek Medical Centre, Pediatric Gastroenterology and Nutrition, Jerusalem, Israel, 2The Hospital for Sick Children, Department of Paediatrics, Toronto, ON, Canada, 3Pontificia Universidad Católica de Chile, Department of Pediatrics, Chile, Chile, 4Rambam Medical Cenetr, Pediatric GI, Haifa, Israel, 5Schneider Children's Medical Center of Israel, Institute of Gastroenterology, Petach Tikva, Israel, 6Hadassah Medical Center, Pediatric GI, Jerusalem, Israel

OP014

Use of anti-TNF-α agents in relation to first-time surgery for ulcerative colitis and Crohn's disease during childhood

Authors:

M.D. Larsen*1, J. Kjeldsen2, N. Qvist3, B. Nørgård1, J. Nielsen1

1Odense University Hospital, Clinical Epidemiology, Odense, Denmark, 2Odense Hospital, Dept. of Medical Gastroenterology S, Odense, Denmark, 3Odense University Hospital, Surgical Department , Odense, Denmark

OP015.

Gut homing markers in perianal Crohn's fistulae

Authors:

N.A. Yassin1, A. Askari1, Y.H. Siaw1, E. Mann2, D. Bernardo2, R.K.S. Phillips1, S. Knight2, H. Al-Hassi2, A.L. Hart1, 1St Mark's Hospital, and Academic Institute, London, United Kingdom, 2Imperial College London, Antigen Presentation Research Group, London, United Kingdom

OP015

Multicentre clinical trial with topical administration of the Toll-Like receptor 9 agonist DIMS0150 shows evidence for efficacy in moderate to severe Ulcerative Colitis

Authors:

R. Atreya*1, S. Bloom2, F. Scaldaferri3, V. Gerardi3, A. Karlsson4, T. Knittel4, J. Kowalski4, M. Lukas5, R. Lofberg6, R. Petryka7, G. Rydzewska8, R. Schnabel9, U. Seidler10, S. Nancey11, M. Neurath12, C. Hawkey13

1University of Erlangen-Nuremberg, Department of Medicine 1, Erlangen, Germany, 2University College London Hospital, Gastroenterology, London, United Kingdom, 3Catholic University of Rome, Internal Medicine/Gastroenterology Division, Rome, Italy, 4InDex Pharmaceuticals, Clinical Research, Stockholm, Sweden, 5Clinical Centre Isacre Lighthouse, IBD Clinical & Research Centre, Prague, Czech Republic, 6Karolinska Institute and Sophiahemmet, Gastro Center, Stockholm, Sweden, 7NZOZ Vivamed, Gastroenterology, Warsaw, Poland, 8Central Clinical Hospital Ministry of Interior in Warsaw, Department of Gastroenterology, Warsaw, Poland, 9Pannonia Maganorvosi Centrum, Gastroenterology, Budapest, Hungary, 10MHH, Dept. of Gastroenterology, Hepatology and Endocrinology, Hanover, Germany, 11Lyon-Sud Hospital, Gastroenterology, Pierre-Benite, France, 12University of Erlangen-Nuremberg, Gastroenterology, Erlangen, Germany, 13University of Nottingham, Nottingham Digestive Diseases Centre, Nottingham, United Kingdom

OP016.

Transethnic association study of IBD identifies 14 new disease loci and demonstrates pervasive sharing of genetic risk factors and phenotypic features between Europeans and non-Europeans

Authors:

R.K. Weersma1, International IBD Genetics Consortium2, 1University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, Netherlands, 2, Netherlands